GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival (PFS) readout ahead of its potential U.S. return in multiple myeloma this ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for multiple myeloma (MM). The health ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the ...

The best hoodies for men combine comfort and style in one convenient package. These are the GQ-favorite picks every guy needs, from Nike, Uniqlo, and more.

A new “trojan horse” drug is being offered on the NHS to give terminal blood cancer patients years more life. NHS England says it is the first health service in the world to offer Blenrep ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

NHS green lights ‘Trojan horse’ treatment that attacks cancer cells from inside One early adopter describes how he was in remission ‘within the first two or three weeks’ after the treatment ...

There’s a lesson to be learned when you look at the best hoodies on Amazon: the best things in life are the simplest. Because decking out a humble hoodie to the nines can feel like cheffing up a ...

The Florida Panthers defeated the Edmonton Oilers to secure their second straight Stanley Cup. Here's how to buy gear including a hat, shirt, hoodie.

The company expects up to £3 billion ($3.97 billion) in peak annual Blenrep sales. It is also studying the drug as a first-line treatment, which could add to that revenue forecast, Miels said.